We believe preserving sight means preserving independence, mobility and a life still fully open.
Grounded in translational retinal research and a rigorous approach to drug development.
Designed with real patients in mind — those who still have no practical treatment option.
Committed to preserving natural vision before it is irreversibly lost.
Luminara is developing P1614, a synthetic peptide-based therapy candidate designed to slow retinal degeneration. Unlike approaches focused on a single genetic mutation, P1614 is being developed as a broader, mutation-agnostic approach with topical eye-drop delivery.
Designed for administration as an eye drop — non-invasive, simple and suited for chronic use in everyday life.
Developed to address retinal degeneration broadly, with the potential to benefit patients regardless of their specific genetic mutation.
Built on synthetic peptide biology, offering a differentiated mechanism with a strong translational rationale.
Peptide-based Synthetic peptide candidate with a clear translational path from bench to clinic.
Topical delivery Eye-drop administration designed for chronic use and real-world adoption.
Broad reach Mutation-agnostic design aimed at the wide population of underserved RP patients.
Many current approaches in inherited retinal disease are highly specific, invasive or difficult to scale. Luminara is focused on a practical therapeutic path: broad eligibility, simple delivery and the potential to preserve natural vision.
Designed to reach beyond single-mutation therapies, with the potential to benefit a wide and diverse RP patient population.
Built around topical eye-drop delivery — no injections, no surgery, no barriers to patient access.
Developed with chronic use and real-world adoption in mind, not just clinical elegance.
Designed as a platform for broad patient impact — a therapy built to reach the many, not the few.
Luminara's work is based on scientific research in retinal neurodegeneration, peptide biology and vision preservation. The company builds on a strong academic and translational foundation, with a development vision focused on turning promising science into a clinically usable therapy candidate.
Grounded in rigorous research on retinal neurodegeneration and peptide-based neuroprotection.
Every development decision is made with the underserved RP patient population in mind.
From academic insight to a clinically viable candidate — designed from the start to reach patients.
Open to partnerships with researchers, ophthalmologists and institutions advancing retinal medicine.
Science-led. Patient-focused. Built for translation.
Luminara brings together expertise in retinal biology, peptide chemistry and translational medicine. Our approach is grounded in the belief that good science, rigorously developed, can become a practical therapy that reaches the patients who need it most.
Luminara Therapeutics is open to conversations with investors, strategic partners, researchers and collaborators who share our commitment to preserving vision.
We welcome conversations with investors who believe in the potential of science-led vision preservation.
Open to collaboration with ophthalmology leaders, retina specialists and pharma organizations.
Interested in connecting with academic and translational researchers in retinal medicine and peptide biology.
© 2026 Luminara Therapeutics SL
Contact: Pilar Najarro, COO & Partner
pnajarro@luminaratherapeutics.com
Our mission is to preserve sight before it is irreversibly lost, starting with Retinitis Pigmentosa — a progressive retinal disease that affects millions of people worldwide.